Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial.
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung YKK, Amico KR, Friedland G, Daftary A, Zelnick JR, Naidoo K, O'Donnell MR. Ross J, et al. Trials. 2023 Dec 1;24(1):776. doi: 10.1186/s13063-023-07520-9. Trials. 2023. PMID: 38037105 Free PMC article.
Differentiated service delivery framework for people with multidrug-resistant tuberculosis and HIV co-infection.
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung K, Amico KR, Brust JCM, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Reis K, et al. J Acquir Immune Defic Syndr. 2024 Feb 6:10.1097/QAI.0000000000003394. doi: 10.1097/QAI.0000000000003394. Online ahead of print. J Acquir Immune Defic Syndr. 2024. PMID: 38323838
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): Study protocol for an adaptive randomized controlled trial.
Ross JE, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung YKK, Amico KR, Friedland G, Daftary A, Zelnick J, Naidoo K, O'Donnell MR. Ross JE, et al. Res Sq [Preprint]. 2023 Jun 9:rs.3.rs-2841179. doi: 10.21203/rs.3.rs-2841179/v1. Res Sq. 2023. Update in: Trials. 2023 Dec 1;24(1):776. doi: 10.1186/s13063-023-07520-9 PMID: 37333087 Free PMC article. Updated. Preprint.